Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Accured Expenses for 4 consecutive years, with $12.1 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 62.91% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.2 million through Dec 2025, down 166.82% year-over-year, with the annual reading at -$15.2 million for FY2025, 166.82% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $12.1 million at Centessa Pharmaceuticals, up from -$689000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $32.7 million in Q4 2024, with the low at -$29.6 million in Q1 2025.
  • Average Change in Accured Expenses over 4 years is $813687.5, with a median of $2.3 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 1501.47% in 2024, while the deepest fall reached 2706.12% in 2024.
  • Over 4 years, Change in Accured Expenses stood at -$4.8 million in 2022, then skyrocketed by 142.28% to $2.0 million in 2023, then soared by 1501.47% to $32.7 million in 2024, then crashed by 62.91% to $12.1 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $12.1 million, -$689000.0, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.